A CASE STUDY OF SASB SPECIFIC-INDUSTRY ESG STANDARD ALIGNING IN PT BIO FARMA
The study identifies critical gaps in Bio Farma's ESG reporting practices, particularly in the context of sustainability metrics which were deemed insufficient by stakeholders and regulatory audits in the lines of comparability and financial materiality. To address these challenges, this resea...
Saved in:
| Main Author: | |
|---|---|
| Format: | Theses |
| Language: | Indonesia |
| Subjects: | |
| Online Access: | https://digilib.itb.ac.id/gdl/view/87228 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Institut Teknologi Bandung |
| Language: | Indonesia |
| Summary: | The study identifies critical gaps in Bio Farma's ESG reporting practices, particularly in the context of sustainability metrics which were deemed insufficient by stakeholders and regulatory audits in the lines of comparability and financial materiality. To address these challenges, this research proposes to adopt the Sustainability Accounting Standards Board (SASB) Biotechnology & Pharmaceuticals standard as complementary to GRI and PJOK and to improve alignment with investor expectations and industry–specific benchmarks.
The study employs a two-pronged methodology: gap analysis and benchmarking analysis. The gap analysis identifies unreported or insufficiently reported SASB metrics across environmental, social, and governance dimensions. Benchmarking analysis examines industry-leading companies’ ESG reporting practices to derive actionable solutions that align Bio Farma with investor expectations and industry-specific financial materiality.
|
|---|